Australia markets open in 5 hours 43 minutes

Cessatech A/S (8GN.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.7260-0.0660 (-8.33%)
At close: 09:16AM CEST

Cessatech A/S

Kanonbådsvej 2
Copenhagen 1437
45 93 87 23 09

Full-time employees2

Key executives

NameTitlePayExercisedYear born
Mr. Jes TrygvedChief Exec. OfficerN/AN/A1973
Benedikte BandakHead of Clinical Devel. & OperationsN/AN/AN/A
Martin JuhlHead of CMC, Device Devel. & OperationsN/AN/AN/A
Louise BakHead of Regulatory AffairsN/AN/AN/A
Etienne AdriansenHead of Bus. Devel.N/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Cessatech A/S engages in identifying and developing drugs for the treatment of medical unmet need in children in Denmark. The company's lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for magnetic resonance imaging scanning; and CT003, a local anesthetic gel for open wounds. The company was incorporated in 2020 and is based in Copenhagen, Denmark.

Corporate governance

Cessatech A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.